COMP <GO>
HCAT vs NVDA // RETURN ON INVESTED CAPITAL (ROIC)
Health Catalyst Inc (NASDAQ) VS. NVIDIA Corporation (NASDAQ) • 15-METRIC TALLY: HCAT 0
— NVDA 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: NVDA
LAST: $1.79 (-0.56%) • MKT CAP: $134.7M
roic
-35.00%
LAST: $213.66 (-0.80%) • MKT CAP: $5.15T
roic
65.06%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HCAT VS. NVDA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HCAT | NVDA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.67% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 65.06% | -100.06 | NVDA | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 23.2x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.18% | 2.58% | -2.76 | NVDA | /fcf-yield <GO> |
| Operating Margin | -51.70% | 65.21% | -116.91 | NVDA | /operating-margins <GO> |
| Net Profit Margin | -57.20% | 63.66% | -120.86 | NVDA | /net-margins <GO> |
| Revenue Growth (YoY) | 1.50% | 83.38% | -81.88 | NVDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.02% | -0.02 | NVDA | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 19.52 | -19.32 | NVDA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 4/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 9.01% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.8 | 51.1 | -4.34 | NVDA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 2.04 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $134.7M | $5.15T | -$5.15T | NVDA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HCAT REV | NVDA REV | HCAT GROSS % | NVDA GROSS % | HCAT FCF | NVDA FCF |
|---|---|---|---|---|---|---|
| FY 2026 | — | $215.94B | — | 71.1% | — | $96.68B |
| FY 2025 | $311.1M | $130.50B | — | 75.0% | -$237.0K | $60.85B |
| FY 2024 | $306.6M | $60.92B | — | 72.7% | $12.9M | $27.02B |
| FY 2023 | $295.9M | $26.97B | — | 56.9% | -$33.1M | $3.81B |
| FY 2022 | — | $26.91B | — | 64.9% | — | $8.13B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HCAT // BETA —
NVDA // BETA 2.04